Thus began the world's current preference for acetaminophen, ibuprofen and other related drugs.
Acetaminophen was identified as a pain reliever in the 1890s, even before aspirin was discovered, but it did not enter widespread use until the 1950s. A small drug company called McNeil Laboratories in Pennsylvania began marketing acetaminophen under the brand name Tylenol in 1955. Unlike aspirin, acetaminophen is strictly an analgesic and antipyretic. It does not reduce inflammation, but nor does it upset the stomach. However, acetaminophen at high doses can cause liver failure. Clearly, no drug is perfect.
In the 1960s, scientists at the Boots Pure Drug Company in the UK discovered that the phenylalkanoic class of acids, of which ibuprofen is a member, are also good pain killers, fever reducers and anti-inflammatory agents. Clinical trials with ibuprofen were conducted in the 1970s, and in the early 1980s it reached drugstore shelves under the trade names of Nuprin, Advil and Motrin. Related compounds, such as naproxen (known as Aleve) and ketoprofen (known as Orudis) are also now available. All of these can cause stomach upset, but usually less so than aspirin.
It is now known that all of these drugs block the activities of cyclooxygenase (COX), enzymes that act early in the pathways of prostaglandin synthesis. So far, three COX enyzymes have been identified: COX-1 is involved in protecting the gastrointestinal tract from acid assault; COX-2 is involved in pain, fever, and inflammation; and the role of the newly discovered COX-3, which is expressed primarily in the brain and heart, remains obscure. Both aspirin and ibuprofen inhibit COX-1 and COX-2, but acetaminophen appears to inhibit only COX-3. Very recently, additional anti-inflammatory agents have been introduced, ones that inhibit COX-2 but not COX-1. These compounds, Celecoxib (known as Celebrex) and rofecoxib (known as Vioxx), have become some of the fastest selling drugs on the market. However, they too have their problems, as they promote blood clotting which may lead to heart attack and stroke in rare cases.
The information from basic research has laid the foundation for the development of drugs against each of the cyclooxygenase subtypes. However, with each powerful drug, new side effects have also emerged. This points to the need to better understand the production and function of various prostaglandins in the body. With increased knowledge in this area, perhaps it will eventually be possible to make yet more specific drugs tailored to each prostaglandin action. One day we may use one drug to dull pain, another to reduce blood clotting, yet another to lower fever, and so forth -a pill for every prostaglandin's purpose. 
